Cardiology; Coronary Disease; Myocardial Ischemia; Humans; American Heart Association; Myocardial Ischemia/diagnosis; Proliferating Cell Nuclear Antigen; United States

AHA Scientific Statements; acute coronary syndrome; air pollution; angina; antiplatelet therapy; aspirin; atherosclerosis; autoimmune diseases; cardiac events; cardiac rehabilitation; cardiovascular diseases; colchicine; coronary artery disease; coronary disease; cost-benefit analysis; depression; diabetes; diet; diet therapy; dietary supplements; drug therapy; dual antiplatelet therapy; environmental exposure; exercise tolerance; factor Xa inhibitors; fibrinolytic agents; glucagon-like peptide-1 receptor agonists; guideline-directed management and therapy; health care outcome assessments; health equity; heart disease risk factors; heart failure; hormone replacement therapy; hypercholesterolemia; hypertension; immunization; ischemic heart disease; mental health; multidisciplinary; myocardial ischemia; outcomes; outpatient; patient care team; pharmacology; pregnancy; proton pump inhibitors; quality of life; safety; secondary prevention; sexual behavior; sexual health; shared decision-making; smoking cessation; social determinants of health; sodium-glucose cotransporter 2 inhibitors; spontaneous coronary artery dissection; stress; therapeutic use; therapy; type 2 diabetes; vaccination